Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Sep 6;24(5):1400-1406.
doi: 10.17305/bb.2024.10433.

Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina

Nermin Salkić  1 , Mirela Bašić Denjagić  2 , Nađa Zubčević  3 , Renata Tamburić  4 , Azra Husić Selimović  5 , Emil Babić  6 , Milenko Bevanda  6 , Aida Saray  3 , Predrag Jovanović  7 , Zoran Tošić  8 , Aleksandar Dobrovoljski  4 , Tatjana Barać  4
Affiliations
Observational Study

Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina

Nermin Salkić et al. Biomol Biomed. .

Abstract

Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), necessitates effective management strategies. This study aims to evaluate the real-world efficacy of vedolizumab, a newer biological therapy, in treating IBD in Bosnia and Herzegovina. A retrospective observational study was conducted across six medical centers, involving 139 IBD patients, 76 with UC and 63 with CD. Patients were assessed for clinical remission and other outcomes at the 26-week mark post vedolizumab treatment initiation. At 26 weeks, clinical remission was achieved in 82.9% of UC patients and 85.7% of CD patients. Mucosal healing was observed in 38.1% of CD patients. The efficacy of vedolizumab did not significantly differ based on prior anti-tumor necrosis factor (anti-TNF) exposure. Notably, the clinical scoring tools for predicting vedolizumab response showed limited applicability in this cohort. Vedolizumab demonstrated high efficacy in treating both UC and CD in real-world settings in Bosnia and Herzegovina, underscoring its potential as a significant therapeutic option in IBD management.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Authors declare no conflicts of interest.

Figures

Figure 1.
Figure 1.
Proportion (95% CI) of Crohn’s disease patients achieving primary and secondary outcomes after 26 weeks of treatment with vedolizumab. CI: Confidence interval.
Figure 2.
Figure 2.
Percentage of Crohn’s disease patients achieving primary and secondary outcomes after 26 weeks of treatment with vedolizumab, categorized by previous anti-TNF drug exposure. anti-TNF: Anti-tumor necrosis factor.
Figure 3.
Figure 3.
Proportion (95% CI) of ulcerative colitis patients achieving primary and secondary outcomes after 26 weeks of treatment with vedolizumab. CI: Confidence interval.
Figure 4.
Figure 4.
Percentage of ulcerative colitis patients achieving primary and secondary outcomes after 26 weeks of treatment with vedolizumab, categorized by previous anti-TNF drug exposure. anti-TNF: Anti-tumor necrosis factor.
Figure 5.
Figure 5.
Percentage of Crohn’s disease patients achieving primary and secondary outcomes after 26 weeks of treatment with vedolizumab, categorized by the clinical probability of response scoring tool described by Dulai et al. [20].
Figure 6.
Figure 6.
Percentage of ulcerative colitis patients achieving primary and secondary outcomes after 26 weeks of treatment with vedolizumab, categorized by the clinical probability of response scoring tool described by Dulai et al. [19].
See this image and copyright information in PMC

References

    1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–57. https://doi.org/10.1016/S0140-6736(07)60751-X. - PubMed
    1. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–78. https://doi.org/10.1016/S0140-6736(17)32448-0. - PubMed
    1. Salkic NN, Pavlovic-Calic N, Gegic A, Jovanovic P, Basic M. Ulcerative colitis in the Tuzla region of Bosnia and Herzegovina between 1995 and 2006: epidemiological and clinical characteristics. Eur J Gastroenterol Hepatol. 2010;22:346–53. https://doi.org/10.1097/MEG.0b013e32832bfe05. - PubMed
    1. Pavlovic-Calic N, Salkic NN, Gegic A, Smajic M, Alibegovic E. Crohn’s disease in Tuzla region of Bosnia and Herzegovina: a 12-year study (1995–2006) Int J Colorectal Dis. 2008;23:957–64. https://doi.org/10.1007/s00384-008-0493-1. - PubMed
    1. Tulumović E, Salkić N, Tulumović D. Inflammatory bowel disease in Tuzla Canton, Bosnia-Herzegovina: a prospective 10-year follow-up. World J Gastroenterol. 2021;27:2630. https://doi.org/10.3748/wjg.v27.i20.2630. - PMC - PubMed

Publication types